Welcome to our dedicated page for Journey Medical SEC filings (Ticker: DERM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Journey Medical Corporation (DERM) SEC filings page on Stock Titan provides access to the company’s public regulatory documents as filed with the U.S. Securities and Exchange Commission. Journey Medical is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription pharmaceutical products for dermatological conditions, with its common stock listed on The Nasdaq Capital Market under the symbol DERM and registered pursuant to Section 12(b) of the Securities Exchange Act of 1934.
Through its SEC filings, investors can review Journey Medical’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe its dermatology-focused business, portfolio of eight branded FDA-approved prescription drugs, risk factors, and financial statements. Current reports on Form 8-K provide updates on material events, including quarterly financial results, amendments to credit agreements, at-the-market equity sales programs, changes to the company’s certificate of incorporation, index inclusion announcements, and disclosures related to the commercialization and pharmacy benefit coverage of Emrosi (DFD-29) for inflammatory lesions of rosacea in adults.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as Journey Medical’s revenue composition, term loan arrangements, equity issuance programs, governance changes, and other significant disclosures. Real-time updates from the EDGAR system ensure that new 8-Ks, 10-Qs, and 10-Ks are reflected promptly, while access to exhibits and related materials allows for deeper review when needed.
In addition, users can monitor forms that disclose capital markets and corporate actions referenced in Journey Medical’s filings. By combining original SEC documents with AI-generated explanations, this page is intended to make Journey Medical’s regulatory history and ongoing reporting more accessible to investors, analysts, and others researching DERM.
Journey Medical Corp Chief Operating Officer Ramsey Alloush received new equity awards as part of compensation. On April 22, 2026, he was granted 46,863 restricted stock units that vest in three equal installments on April 22 of 2027, 2028, and 2029. He also received stock options for 62,795 shares of common stock at an exercise price of $5.04 per share, vesting on the same dates. After these awards, he directly owns 598,543 shares of common stock, including restricted stock units. The options expire on April 22, 2036, giving him long-term upside exposure tied to the company’s share price.
Journey Medical Corp CFO Joseph Benesch received new equity awards as part of his compensation. On April 22, 2026, he was granted 28,907 restricted stock units that vest in three annual installments from April 2027 through April 2029. He also received 41,860 stock options with an exercise price of $5.04 per share, vesting annually over the same three-year period and expiring in 2036. After these awards, he directly holds 261,371 shares of common stock, and has 41,860 options outstanding.
Journey Medical Corp reported that President & CEO Claude Maraoui received new equity awards as part of his compensation. On April 22, 2026, he was granted 49,277 restricted stock units that vest in three equal annual installments from 2027 through 2029.
He was also granted stock options for 82,915 shares at an exercise price of $5.04 per share, vesting on the same 2027–2029 schedule and expiring in 2036. Following these grants, Maraoui directly holds 2,435,990 shares of common stock and 82,915 options.
Journey Medical Corporation reported a major expansion in payer coverage for Emrosi™, its oral treatment for inflammatory lesions of rosacea in adults. After securing a contract with a third major group purchasing organization, Emrosi™ payer access increased from approximately 100 million to over 150 million commercial lives as of April 1, 2026.
The company states that about 85% of all commercial lives in the United States now have access to Emrosi™, which it expects will support growth in total prescriptions, broader formulary adoption through 2026 and beyond, and reduced reliance on its co-pay bridging program.
Journey Medical Corp ownership disclosure: Wasatch Advisors reports beneficial ownership of 2,133,370 shares, representing 10.0% of the common stock as reported 03/31/2026. The filing shows sole voting power for 1,979,366 shares and sole dispositive power for 2,133,370 shares.
Journey Medical Corporation outlines its dermatology-focused business in its annual report, highlighting a portfolio of eight FDA‑approved prescription products and several legacy brands. The company concentrates on acne, rosacea, hyperhidrosis, fungal infections, pruritus and wound care, selling mainly through specialty pharmacies and distributors in the U.S.
In 2024 the FDA approved Emrosi, a low‑dose oral minocycline for rosacea, which launched commercially in 2025 and is protected by patents through 2039. Journey also markets Qbrexza, Amzeeq, Zilxi and Accutane under multiple in‑license and acquisition agreements that include milestones and royalties.
The report emphasizes growth via additional product licenses and acquisitions, notes new out‑licensing deals in Asia, and describes reliance on third‑party manufacturers and partners. It also details extensive intellectual property, regulatory and healthcare compliance frameworks, and key risks such as generic competition, pricing pressure, and Fortress Biotech’s voting control.
Journey Medical Corporation reported full-year 2025 results with total revenues of $61.9 million, up from $56.1 million in 2024. Net loss narrowed to $11.4 million compared with $14.7 million a year earlier, and GAAP net loss per share improved to $0.47 from $0.72.
The company generated non-GAAP Adjusted EBITDA of $2.9 million, up from $0.8 million in 2024, reflecting higher product revenue and lower research and development spending. Cash and cash equivalents were $24.1 million as of December 31, 2025, compared with $20.3 million at year-end 2024.
Management highlighted the launch of Emrosi™, which generated $14.7 million in net revenues in 2025 after its early April launch, with approximately 53,000 prescriptions filled and payer access to over 100 million U.S. commercial lives.
Journey Medical Corporation is launching an at-the-market offering of up to 3,750,000 shares of common stock under a sales agreement with B. Riley Securities and Lake Street Capital. The shares may be sold from time to time on The Nasdaq Capital Market at prevailing prices, with the Agents receiving a 3.0% commission on gross proceeds and being deemed underwriters. If all shares were sold at a recent price of $7.27, the company illustrates potential gross proceeds of about $27.3 million and an increase in net tangible book value per share, but also immediate dilution of $6.49 per share to new investors. Journey plans to use any net proceeds for general corporate purposes, including working capital, research and development, licensing payments, sales and marketing, and capital expenditures. The company highlights that investors face dilution risk, stock price volatility from ongoing ATM sales, and that an independent auditor has raised substantial doubt about its ability to continue as a going concern.
Journey Medical Corporation has filed a shelf registration that allows it to offer up to $150,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. The company can sell these securities in one or more offerings, separately or bundled in units, with specific terms and pricing to be detailed in future prospectus supplements. Net proceeds may be used for general corporate purposes, including working capital, research and development, licensing payments, sales and marketing, administrative expenses and capital expenditures. Journey is a commercial-stage pharmaceutical company focused on FDA-approved dermatology products, including the recently approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for inflammatory lesions of rosacea in adults. The company is controlled by Fortress Biotech through Class A Common Stock with majority voting power and is classified as both an emerging growth company and a smaller reporting company. The independent auditor’s report on the 2024 financial statements includes an explanatory paragraph noting recurring losses from operations that raise substantial doubt about Journey’s ability to continue as a going concern.